UnknownNCT04433858
An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)
This study evaluates the safety and effectiveness of Psilocybin for people with depression.
Medication studyAges 18–65United States
Understand this study
What is this study about?
This study evaluates the safety and effectiveness of Psilocybin for people with depression.
Who could participate?
This study is for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
- Listed locations
- Palo Alto and 1 more locationSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: March 1, 2021
- Recruitment status
- Unknown
- Enrollment listed in the registry
- 27
- Sponsor
- Sheppard Pratt Health System
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT04433858
- Official title
Show the full official title
An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)
Recruitment & locations
Status unknownPalo Alto · Baltimore
A listed location does not confirm current availability.
Questions about this study
What is this study about?
This study evaluates the safety and effectiveness of Psilocybin for people with depression.
Who is behind this study?
The study sponsor is Sheppard Pratt Health System.
Does this study involve medication?
Yes. The study involves medication, including Psilocybin.
Who can participate?
This study is for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
